BioSpace News Archive

MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced that it will release financial results for the first quarter of 2022 after the U.S. market close on Monday, May 9th, 2022.

Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that it will release its first quarter 2022 financial results on Wednesday, May 4, 2022.

ReWalk Robotics. Ltd. announced that the Board has approved the appointment of Joseph Turk, Jr. to the Board of Directors.

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2022 financial results on Wednesday, May 4, 2022, before the open of the US financial markets.

Domus Diagnostics announced that it has exited stealth mode and will begin clinical testing of its COVID-19 testing platform that could significantly address the global need for accessible, rapid, Nucleic Acid Amplification Tests (NAAT).

Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), announces today that the first patient with advanced, refractory gastrointestinal cancer has been dosed in its amended maximum tolerated dose (MTD) Phase 1B trial for Next Generation Capecitabine (the combination of PCS6422 and capecitabine) (NCT04861987).

Thermo Fisher Scientific celebrated the opening of its new single-use technology manufacturing site in Ogden, Utah.

Omeros Corporation (Nasdaq: OMER) today announced the online publication of a manuscript detailing the results of its pivotal study assessing efficacy and safety of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), an often-lethal complication of stem-cell transplantation for which there is no approved treatment.

Alcon will once again have a significant scientific presence at the American Society of Cataract and Refractive Surgery 2022 Annual Meeting, taking place April 22-26 in Washington, D.C. Approximately 150 abstracts feature Alcon’s leading ophthalmic products and equipment—with more than 60 sponsored by Alcon—reinforcing the company’s continued commitment to research and innovation.

Selva Therapeutics, Inc. (“Selva”) today announced new preclinical data demonstrating dosing of SLV213 at picomolar concentrations delivered near complete inhibition of infection by the Omicron variant of SARS-CoV-2 in a human lung epithelial cell line (A549_ACE2).